Journal
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 58
Volume 58, Issue -, Pages 625-648Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-010617-052912
Keywords
KCNQ genes; K(v)7 channel; epilepsy; retigabine; smooth muscle contraction; arrhythmia
Categories
Funding
- British Heart Foundation [PG/15/97/31862, PG/12/63/29824] Funding Source: Medline
- Medical Research Council [MR/K019074/1] Funding Source: Medline
- MRC [MR/K019074/1] Funding Source: UKRI
- Novo Nordisk Fonden [NNF13OC0006553] Funding Source: researchfish
Ask authors/readers for more resources
K(v)7 channels are voltage-gated potassium channels encoded by KCNQ genes that have a considerable physiological impact in many cell types. This reliance upon K(v)7 channels for normal cellular function, as well as the existence of hereditary disorders caused by mutations to KCNQ genes, means that pharmacological targeting of these channels has broad appeal. Consequently, a plethora of chemical entities that modulate K(v)7 channel activity have been developed. Moreover, K(v)7 channels are influenced by many disparate intracellular mediators and trafficking processes, making upstream targeting an appealing prospect for therapeutic development. This review covers the main characteristics of these multifunctional and versatile channels with the aim of providing insight into the therapeutic value of targeting these channels.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available